2nd International Conference on Non-invasive Cardiac Imaging, Nuclear Cardiology & Echocardiography
Amsterdam, Netherlands
Hossein Tabriziani
Loma Linda University, USA
Title: Hypertension & cardiovascular disease after kidney transplantation
Biography
Biography: Hossein Tabriziani
Abstract
The incidence of end stage renal disease (ESRD) continues to rise in the United States. By the year 2030, the number of patients with ESRD is projected to exceed 2.2 million. This is more than five times the current prevalence.
During the past decade, kidney transplantation has increasingly been recognized as the treatment of choice for medically suitable patients with ESRD. As well as improving quality of life, successful transplantation confers major benefits by improving morbidity and mortality of ESRD patients who receive kidney transplant over those who undergo renal replacement therapy (RRT). Cardiovascular (CV) risk reduction remains the leading cause of this improvement, although both modalities provide compatible fluid balance and glomerular filtration.
As the Uited States Renal Data System (USRDS) shows, mortality is improved significantly for ESRD patients who received renal transplantation as compared to those with RRT.
Oxidative stress plays a key role in the pathophysiological process of uremia and its complications, particularly in cardiovascular disease. The level of oxidative stress markers is known to increase as Chronic Kidney Disease (CKD) progresses and correlates significantly with level of renal function.
Successful kidney transplantation, results in near normalization of the antioxidant status and lipid metabolism by eliminating free radicals despite the surge of oxidative stress caused by the surgical procedure and ischemic injury to the organ during the operation. This success is associated with both improved renal function, reduced cardiovascular complications, and overall improved morbidity and mortality.
